Mendus Q3 2024: Minor catalysts in Q4 2024e, CADENCE in focus - Redeye

Redeye provides its comment on Mendus’ Q3 2024 report. We judge ADVANCE II and ALISON readouts might act as minor catalysts in Q4 2024e. We believe CADENCE readouts will be major catalysts in the coming 12-24 months. Its estimated funding runway extends past several of these catalysts. We update our deal estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1054491/mendus-q3-2024-minor-catalysts-in-q4-2024e-cadence-in-focus?utm_source=finwire&utm_medium=RSS